Century Therapeutics, Inc. (IPSC)

Every figure this model derived for IPSC, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 848,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 119,712,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 124,768,000 AssetsCurrent 2026-06-30
current liabilities 15,068,000 LiabilitiesCurrent 2026-06-30
equity 232,345,000 StockholdersEquity 2026-06-30
ocf -86,757,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 109,164,000 RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31
sbc 5,587,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up IPSC on one particular measure came for.

RatioValue
cash operating margin-93.16
current ratio8.28
current ratio reported8.28
deferred revenue growth2396.89
dilution pct10.06
fcf margin-80.25
growth cv1.25
operating margin-107.17
owner earnings margin-85.37
revenue growth1556.51
revenue growth per share1405.08
roic-82.06
rpo growth-0.01
rule of 401449.34
sbc pct revenue5.12

What to be careful about

What this model itself distrusts about IPSC's figures. Written by the derivation as it ran, not added afterwards.